Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KYSA-1: KYV-101 in Refractory Lupus Nephritis
NCT05938725Phase 2Terminated
- Sponsor
- Kyverna Therapeutics
- Start
- Apr 2023
- Primary completion
- May 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of mivocabtagene autoleucel in lupus nephritis (LN), sponsored by Kyverna Therapeutics. Started Apr 2023; status: terminated.
02
Drugs
mivocabtagene autoleucel
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT05938725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05938725.